Inhibitors of PCSK9 for treatment of lipoprotein metabolism disorders
First Claim
Patent Images
1. An antibody or antigen-binding fragment thereof that specifically binds a binding region within the HSPG binding site of PCSK9 (SEQ ID NO:
- 1), said site within amino acid residues 78 to 167 of PCSK9 (SEQ ID NO;
1), wherein;
(a) the antibody or antigen-binding fragment thereof comprises;
(i) a heavy chain variable region or a humanized version thereof, comprising three CDRs, wherein heavy chain CDR1 comprises SEQ ID NO;
10;
heavy chain CDR2 comprises SEQ ID NO;
11; and
heavy chain CDR3 comprises SEQ ID NO;
12, and(ii) a light chain variable region or a humanized version thereof, comprising three CDRs, wherein light chain CDR1 comprises SEQ ID NO;
13;
light chain CDR2 comprises SEQ ID NO;
14; and
light chain CDR3 comprises SEQ ID NO;
15;
or(b) the antibody or antigen-binding fragment thereof comprises;
(i) a heavy chain variable region or a humanized version thereof, comprising three CDRs, wherein heavy chain CDR1 comprises SEQ ID NO;
16;
heavy chain CDR2 comprises SEQ ID NO;
17; and
heavy chain CDR3 comprises SEQ ID NO;
18, and(ii) a light chain variable region or a humanized version thereof, comprising three CDRs, wherein light chain CDR1 comprises SEQ ID NO;
19;
light chain CDR2 comprises SEQ ID NO;
20; and
light chain CDR3 comprises SEQ ID NO;
21.
1 Assignment
0 Petitions
Accused Products
Abstract
The present disclosure relates to inhibitors of proprotein convertase subtilisin-like/kexin type 9 (PCSK9) for the treatment of lipoprotein metabolism disorders.
-
Citations
10 Claims
-
1. An antibody or antigen-binding fragment thereof that specifically binds a binding region within the HSPG binding site of PCSK9 (SEQ ID NO:
- 1), said site within amino acid residues 78 to 167 of PCSK9 (SEQ ID NO;
1), wherein;(a) the antibody or antigen-binding fragment thereof comprises; (i) a heavy chain variable region or a humanized version thereof, comprising three CDRs, wherein heavy chain CDR1 comprises SEQ ID NO;
10;
heavy chain CDR2 comprises SEQ ID NO;
11; and
heavy chain CDR3 comprises SEQ ID NO;
12, and(ii) a light chain variable region or a humanized version thereof, comprising three CDRs, wherein light chain CDR1 comprises SEQ ID NO;
13;
light chain CDR2 comprises SEQ ID NO;
14; and
light chain CDR3 comprises SEQ ID NO;
15;
or(b) the antibody or antigen-binding fragment thereof comprises; (i) a heavy chain variable region or a humanized version thereof, comprising three CDRs, wherein heavy chain CDR1 comprises SEQ ID NO;
16;
heavy chain CDR2 comprises SEQ ID NO;
17; and
heavy chain CDR3 comprises SEQ ID NO;
18, and(ii) a light chain variable region or a humanized version thereof, comprising three CDRs, wherein light chain CDR1 comprises SEQ ID NO;
19;
light chain CDR2 comprises SEQ ID NO;
20; and
light chain CDR3 comprises SEQ ID NO;
21. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10)
- 1), said site within amino acid residues 78 to 167 of PCSK9 (SEQ ID NO;
Specification